Masimo Co. (NASDAQ:MASI) Shares Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. grew its position in Masimo Co. (NASDAQ:MASI) by 51.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,085 shares of the medical equipment provider’s stock after purchasing an additional 1,043 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Masimo were worth $510,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC raised its holdings in shares of Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. Blue Trust Inc. grew its position in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares during the last quarter. CIBC Asset Management Inc grew its position in shares of Masimo by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider’s stock valued at $270,000 after buying an additional 87 shares during the last quarter. MML Investors Services LLC grew its position in shares of Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after buying an additional 96 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in shares of Masimo by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 12,300 shares of the medical equipment provider’s stock valued at $2,033,000 after buying an additional 100 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on MASI shares. Wells Fargo & Company increased their target price on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Price Performance

Masimo stock opened at $174.52 on Friday. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88. The firm has a 50 day moving average price of $174.95 and a 200 day moving average price of $156.02. The company has a market cap of $9.42 billion, a price-to-earnings ratio of 120.36 and a beta of 1.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Sell-side analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.